Tag Archives: Michael Higgins

Armata Pharmaceuticals Inc (ARMP) Gets a Buy Rating from Ladenburg Thalmann & Co.

Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMP – Research Report) on August 19 and set a price target of $9. The company’s shares closed last Monday at $4.40, close to its

Novus Therapeutics, Inc. (NVUS) Gets a Buy Rating from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Novus Therapeutics, Inc. (NVUS – Research Report), with a price target of $10. The company’s shares closed last Monday at $0.79, close to

Intec Pharma Ltd (NTEC) Receives a Hold from Ladenburg Thalmann & Co.

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Hold rating on Intec Pharma Ltd (NTEC – Research Report), with a price target of $0.50. The company’s shares closed on Friday at $0.46, close to

Ladenburg Thalmann & Co. Sticks to Their Buy Rating for Eiger Biopharmaceuticals (EIGR)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals (EIGR – Research Report), with a price target of $28. The company’s shares closed on Friday at $10.19. Higgins commented: “We

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Achieve Life Sciences Inc (ACHV)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences Inc (ACHV – Research Report), with a price target of $20. The company’s shares closed yesterday at $1.85. According to

Ladenburg Thalmann & Co. Thinks Marinus’ Stock is Going to Recover

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Marinus (MRNS – Research Report), with a price target of $3. The company’s shares closed yesterday at $1.16, close to its 52-week low